

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/088,587 03/21/2002		Tsutomu Okubo	1422-0520P	4925	
2292 75	90 01/11/2006		EXAMINER		
	VART KOLASCH & 1	KIM, VICKIE Y			
PO BOX 747 FALLS CHURG	CH, VA 22040-0747	ART UNIT	PAPER NUMBER		
11111111	, ,		1618		
			DATE MAILED: 01/11/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	on No	Applicant(s)		
Office Action Summary		10/088,58		OKUBO ET AL.		
		Examiner		Art Unit	1	
		Vickie Kim		1618		
Period fo	The MAILING DATE of this communic		<u> </u>		dress	
A SH WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MA Insions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this community operiod for reply is specified above, the maximum stature to reply within the set or extended period for reply with	ILING DATE OF TH 37 CFR 1.136(a). In no evolication. tory period will apply and w II, by statute, cause the app	HIS COMMUNICATION ent, however, may a reply be tin Il expire SIX (6) MONTHS from lication to become ABANDONE	N. nely filed the mailing date of this o D (35 U.S.C. § 133).		
Status						
1)□ 2a)⊠ 3)□	Responsive to communication(s) filed This action is FINAL . 2b Since this application is in condition for closed in accordance with the practice	n) ☐ This action is nor allowance except	for formal matters, pro		e merits is	
Disposit	ion of Claims					
5)□ 6)⊠ 7)□ 8)□ Applicat	Claim(s) 1-11,13,14,16 and 17 is/are page 4a) Of the above claim(s) 1-7 and 16 is Claim(s) is/are allowed. Claim(s) 8-11, 13-14 and 17 is/are rejudent of the claim(s) is/are objected to. Claim(s) are subject to restriction Papers The specification is objected to by the The drawing(s) filed on is/are: a	s/are withdrawn from ected. on and/or election r Examiner.	n consideration. equirement.	Examiner.		
_	Applicant may not request that any objection Replacement drawing sheet(s) including the oath or declaration is objected to be	on to the drawing(s) the correction is requir	pe held in abeyance. See ed if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 C	` '	
Priority (under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
2)	et(s) se of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (PTO mation Disclosure Statement(s) (PTO-1449 or P		4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate	O-152)	

Art Unit: 1618

DETAILED ACTION

Election acknowledged

1. Applicants' election with traverse the invention group II of claims 8-11, 13, 14, 17 is acknowledged. Applicants traverse the restriction requirement on the grounds that there would be no burden in searching all the inventions. However, this argument is not persuasive, as not all inventions encompassed by the genus would be classified together, or each invention may not be anticipated by others because each invention is patentably distinct to each other as evidenced by numerous patents(see US4634588).

Furthermore, even if there were unity of classification, the search of the entire genus in the non-patent(a significant part of a thorough examination) would be burdensome. Theanine is amino acid where it has multiple function and involves various bio-mechanisms. For example, US4624588 uses theanine in deordorizing composition. It is also well known in the art that no single drug controls all types of disorders. Thus, each invention is found to be patentably independent and distinct, further burdensome. Therefore, the restriction requirement is maintained, and made FINAL.

Status of Application

1. Acknowledgement is made of amendment filed 11/8/2004. Upon entering the amendment, the claims 12 and 15 are canceled. The claims 1-11 and 13-14 are amended. New claims 16-17 are added.

Art Unit: 1618

2. Claims 1-11, 13-14, 16-17 are now pending. The elected claims 8-11, 13, 14, 17 have been examined. All remaining claims not drawn to the elected invention are withdrawn from further consideration as being non-elected. The following rejections are made.

Response to Arguments

3. Applicant's arguments filed 11/8/2004 have been fully considered but they are not persuasive.

112 1st rejection

The amended claims now recite stopping smoking; or preventin g to eliminating withdrawal symptoms. However, the specification or any clinical test result fail o show complete stopping enabled. Without guideline or evidential support, the claimed limitation is not considered to be enabling in view of conventional knowledge that is well accepted by ordinary skilled artisan.

Claim Rejections - 35 USC § 112, enablement

The claim 9 is rejected under 35 USC 112, first paragraph, because the specification, while arguably enabling for regulating the desire for smoking or otherwise suppress craving for nicotine, does not reasonably provide enablement for stopping smoking; or prevention or elimination of withdrawal symptoms.

As previously mentioned in previous office action(see 8/6/04), The specification does not enable any person skilled in the art to which it pertains, or with which it is most

Application/Control Number: 10/088,587

Art Unit: 1618

nearly connected, to make/use the invention commensurate in scope with the claim.

Detailed rejection is substantially same as one issued(8/6/04, In re Wands).

As evidenced by fig. 10(10/10), craving for smoking has not been completely subsided. Therefore, the stopping smoking by having theanine administered is not been enabled but is enabling suppressing craving for smoking or reducing smoking.

For the same reason, preventing withdrawal symptoms can not be enabled wherein the administration of theanine is enabling alleviating withdrawal symptoms caused by stopping smoking or moderation of smoking. In addition to that, the craving for smoking or sithdrawal symptoms is not only caused by, or associated by high blood concentration of nicotine(biological stress) but also caused by emotional stress and behavior stress(e.g. habits). Thus, complete stopping smoking; or prevention or elimination of withdrawal symptoms is not fully enabled.

103 rejection

a. In response to applicant argument that the rejection is arrived by "picking and choose" because there are other ingredients are involved in invention disclosed in US'724(Blum) patent. However, the argument is not fully persuasive because the scope of instant claims are also drawn to be broad enough where the other ingredients can be included with different labels(e.g. second or third active ingredients having different biological activity) because the instant claims use open transitional phrase such as "comprising". In response to applicant's argument that the references fail to show certain features of applicant's invention,

Art Unit: 1618

it is noted that the features upon which applicant relies (i.e., a composition consisting essentially of theanine) are not recited in the rejected claim(s), whereas the instant claims are drawn to a composition comprising a smoking craving suppressing substance consisting essentially of theanine. It is conventionally known to any skilled artisan that a chemical compound show more than one biological function. Therefore, the limiting the ingredients with labeling rather than differentiating structure of the composition can not be used to obviate the composition taught by the prior art of the record and still encompassed by the teaching of Blum(US'724). The proposed amendment below would obviate 103 rejection.

103 Rejection

Substantially same.

Proposed Examiner's Amendment

- 4. A proposed examiner's amendment to the record appears below. This examiner's amendment was proposed to applicant on 12/22/05 but not resolved(agreed) in time given. An indication of proposed amendment was requested in a telephone interview with Mr. *** (associate with Mr. Murphy G. Jr) on 12/23/05.
- 5. The application has been amended as follows:
 - a. Cancel non-elected claims 1-8 and 16.
 - In claim 8, line 1, replace [stopping smoking] with -- suppressing craving
 for smoking-- right after "for".

Page 6

Application/Control Number: 10/088,587

Art Unit: 1618

- c. In claim 8, line 3, replace [a composition comprising a smoking craving suppressing substance] with --- a smoking craving suppressing composition --- .
- c. In claim 9, lines 2-3, delete [preventing,] and [or eliminating] right after "for".
- Alternatively, it is suggested that [stopping, preventing or eliminating] can be replaced with --reducing or decreasing --.

Conclusion

- 6. No claim is allowed.
- 7. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1618

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 571-272-0579. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Patent Examiner

January 9, 2006

Art unit 1618